Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vera Therapeutics ( (VERA) ) has shared an announcement.
On August 5, 2025, Vera Therapeutics entered into a new Sales Agreement with TD Securities (USA) LLC, replacing a previous agreement from June 2022. This agreement allows Vera Therapeutics to offer and sell up to $200 million of its Class A common stock through TD Cowen, with the sales subject to certain conditions and limitations. The arrangement provides flexibility in the sale of shares, including at-the-market offerings, and includes a commission of up to 3% for TD Cowen. The impact of this agreement could enhance Vera Therapeutics’ financial flexibility and market presence.
The most recent analyst rating on (VERA) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Vera Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing transformative therapies for patients with serious immunological diseases.
Average Trading Volume: 1,746,419
Technical Sentiment Signal: Sell
Current Market Cap: $1.34B
See more insights into VERA stock on TipRanks’ Stock Analysis page.